Segment information (Tables)

6 Months Ended

Jan. 31, 2017

Segment Reporting [Abstract]

Reportable Segment Information

The tables below present information about our reportable segments:

	Three Months Ended						Six Months Ended
	January 31,						January 31,
(in millions)	2017			2016			2017			2016
Product revenue:
Medical Imaging	$	71.2		$	72.4		$	137.7		$	136.8
Ultrasound		40.3			42.6			75.9			79.1
Security and Detection		18.8			10.9			37.0			24.2
Total product revenue	$	130.3		$	125.9		$	250.6		$	240.1
Engineering revenue:
Medical Imaging	$	1.2		$	1.1		$	1.9		$	1.7
Ultrasound		—			0.7			0.2			0.9
Security and Detection		—			0.2			—			0.2
Total engineering revenue	$	1.2		$	2.0		$	2.1		$	2.8
Net revenue:
Medical Imaging	$	72.4		$	73.5		$	139.6		$	138.5
Ultrasound		40.3			43.3			76.1			80.0
Security and Detection		18.8			11.1			37.0			24.4
Total net revenue	$	131.5		$	127.9		$	252.7		$	242.9
Income from operations:
Medical Imaging (A)	$	12.2		$	11.6		$	18.9		$	18.0
Ultrasound (B)		(4.5	)		(9.9	)		(10.3	)		(14.5	)
Security and Detection (C )		1.8			(0.2	)		4.8			—
Total income from operations		9.5			1.5			13.4			3.5
Total other income (loss), net		0.03			(3.5	)		(0.4	)		(4.0	)
Income (loss) before income taxes	$	9.5		$	(2.0	)	$	13.0		$	(0.5	)

	As of		As of
	January 31,		July 31,
(in millions)	2017		2016
Identifiable total assets by segment:
Medical Imaging	$	179.9	$	191.1
Ultrasound		142.2		152.5
Security and Detection		43.3		49.8
Total reportable segment assets		365.4		393.4
Corporate assets (D)		198.9		165.6
Total identifiable assets	$	564.3	$	559.0

(A) Includes restructuring charges of $0.09 million and $1.9 million for three months ended January 31, 2017 and January 31, 2016, respectively and $0.11 million and $4.0 million for six months January 31, 2017 and January 31, 2016.

(B) Includes restructuring charges of $0.17 million and $0.6 million for three months ended January 31, 2017 and January 31, 2016, respectively and $0.18 million and $1.3 million for six months January 31, 2017 and January 31, 2016.

Includes contingent consideration charges of $(8.2) million and $(8.1) million related to Oncura for three and six months ended January 31, 2017, respectively, asset impairment charges of $9.8 million related to Oncura for three and six months ended January 31, 2017, charges for the BK Medical matter of $10.1 million for three and six months ended January 31, 2016.

(C) Includes restructuring charges of $0.01 million and $0.6 million for three months ended January 31, 2017 and January 31, 2016, respectively and $0.01 million and $1.2 million for six months January 31, 2017 and January 31, 2016.

Includes asset impairment charges of $0.6 million related to Pathfinder for three and six months ended January 31, 2017.

(D) Includes cash and cash equivalents of $139.9 million and $97.3 million as of January 31, 2017 and July 31, 2016, respectively.